Pharmaron Beijing Co., Ltd. (SHE:300759)

Market Cap	51.53B +12.5%
Revenue (ttm)	14.10B +14.8%
Net Income	1.66B -7.2%
EPS	0.94 -7.1%
Shares Out	1.83B
PE Ratio	32.44
Forward PE	26.69
Dividend	0.20 (0.66%)
Ex-Dividend Date	Jul 4, 2025

Volume	37,760,346
Average Volume	37,893,812
Open	30.66
Previous Close	31.39
Day's Range	30.18 - 31.37
52-Week Range	21.99 - 37.63
Beta	0.91
RSI	57.55
Earnings Date	Mar 30, 2026

About Pharmaron Beijing

Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleot...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 25,088
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300759

Financial Performance

In 2025, Pharmaron Beijing's revenue was 14.10 billion, an increase of 14.82% compared to the previous year's 12.28 billion. Earnings were 1.66 billion, a decrease of -7.22%.